489 related articles for article (PubMed ID: 30633615)
41. Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan.
Nakamura S; Mikami M; Hayamizu T; Yonemoto N; Moyon C; Gouldson M; Crossan C; Vietri J; Kamei K
Expert Rev Vaccines; 2024; 23(1):546-560. PubMed ID: 38703180
[TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China.
Mo X; Gai Tobe R; Liu X; Mori R
Pediatr Infect Dis J; 2016 Nov; 35(11):e353-e361. PubMed ID: 27753771
[TBL] [Abstract][Full Text] [Related]
43. Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions.
Treskova M; Scholz SM; Kuhlmann A
Pharmacoeconomics; 2019 Sep; 37(9):1093-1127. PubMed ID: 31025189
[TBL] [Abstract][Full Text] [Related]
44. Cost-Utility Study of PCV13 Versus PPSV23 in Adults in Chile.
Biagini L; Pezzani M; Rojas R; Fuentealba F
Value Health Reg Issues; 2018 Dec; 17():194-201. PubMed ID: 30447540
[TBL] [Abstract][Full Text] [Related]
45. Cost-effectiveness of the 13-valent Pneumococcal Conjugate Vaccine in Children in Portugal.
Gouveia M; Fiorentino F; Jesus G; Costa J; Borges M
Pediatr Infect Dis J; 2017 Aug; 36(8):782-787. PubMed ID: 28288018
[TBL] [Abstract][Full Text] [Related]
46. Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England.
van Hoek AJ; Miller E
PLoS One; 2016; 11(2):e0149540. PubMed ID: 26914907
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.
Earnshaw SR; McDade CL; Zanotti G; Farkouh RA; Strutton D
BMC Infect Dis; 2012 Apr; 12():101. PubMed ID: 22530841
[TBL] [Abstract][Full Text] [Related]
48. Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model.
By A; Sobocki P; Forsgren A; Silfverdal SA
Clin Ther; 2012 Jan; 34(1):177-89. PubMed ID: 22284997
[TBL] [Abstract][Full Text] [Related]
49. Pneumococcal Vaccination Strategies in 50-Year-Olds to Decrease Racial Disparities: A US Societal Perspective Cost-Effectiveness Analysis.
Altawalbeh SM; Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
Value Health; 2024 Jun; 27(6):721-729. PubMed ID: 38462225
[TBL] [Abstract][Full Text] [Related]
50. Economic evaluation of second generation pneumococcal conjugate vaccines in Norway.
Robberstad B; Frostad CR; Akselsen PE; Kværner KJ; Berstad AK
Vaccine; 2011 Nov; 29(47):8564-74. PubMed ID: 21945264
[TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.
Boccalini S; Bechini A; Levi M; Tiscione E; Gasparini R; Bonanni P
Hum Vaccin Immunother; 2013 Mar; 9(3):699-706. PubMed ID: 23295824
[TBL] [Abstract][Full Text] [Related]
52. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis.
Rozenbaum MH; van Hoek AJ; Fleming D; Trotter CL; Miller E; Edmunds WJ
BMJ; 2012 Oct; 345():e6879. PubMed ID: 23103369
[TBL] [Abstract][Full Text] [Related]
53. An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis.
Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
Hum Vaccin Immunother; 2019; 15(4):863-872. PubMed ID: 30633706
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru.
Mezones-Holguin E; Canelo-Aybar C; Clark AD; Janusz CB; Jaúregui B; Escobedo-Palza S; Hernandez AV; Vega-Porras D; González M; Fiestas F; Toledo W; Michel F; Suárez VJ
Vaccine; 2015 May; 33 Suppl 1():A154-66. PubMed ID: 25919156
[TBL] [Abstract][Full Text] [Related]
55. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
56. Towards the introduction of pneumococcal conjugate vaccines in Bhutan: A cost-utility analysis to determine the optimal policy option.
Dorji K; Phuntsho S; Pempa ; Kumluang S; Khuntha S; Kulpeng W; Rajbhandari S; Teerawattananon Y
Vaccine; 2018 Mar; 36(13):1757-1765. PubMed ID: 29478752
[TBL] [Abstract][Full Text] [Related]
57. Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection.
Marbaix S; Peetermans WE; Verhaegen J; Annemans L; Sato R; Mignon A; Atwood M; Weycker D
PLoS One; 2018; 13(7):e0199427. PubMed ID: 29979689
[TBL] [Abstract][Full Text] [Related]
58. Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016.
Vila-Corcoles A; Hospital I; Ochoa-Gondar O; Satue E; de Diego C; Vila-Rovira A; Gómez-Bertomeu F; Raga X; Aragón M
Vaccine; 2020 Jan; 38(5):1170-1180. PubMed ID: 31759735
[TBL] [Abstract][Full Text] [Related]
59. Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea.
Kang DW; Kim CR; Song JY; Park SK
Vaccine; 2024 Feb; 42(4):871-878. PubMed ID: 38225184
[TBL] [Abstract][Full Text] [Related]
60. Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis.
Ta A; Kühne F; Laurenz M; von Eiff C; Warren S; Perdrizet J
Infect Dis Ther; 2024 Jun; 13(6):1333-1358. PubMed ID: 38733494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
